Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study

BMC Urology

Table 2 Perioperative data

Parameter	ThuVEP	TURP	p
Resected weight (g)*	21.3 ± 14.3	37.4 ± 23.0	0.024
Preoperative hemoglobin level (g/dL)	12.9 ± 1.7	13.3 ± 1.6	0.587
Decrease in hemoglobin level (g/dL)	0.5 ± 1.3	0.5 ± 1.1	0.844
Decrease in serum sodium level (mmol/L)	0.3 ± 2.4	1.6 ± 2.0	0.468
Duration of catheterization (day)*	1.8 ± 0.5	2.3 ± 0.5	0.001
Total duration of hospitalization (days)	5.2 ± 1.9	5.2 ± 0.8	0.203
Postoperative duration of hospitalization (days)*	3.0 ± 0.9	3.4 ± 0.7	0.032
Estimated residual prostate volume ratio (V2/V1)	0.47 ± 0.17	0.47 ± 0.20	0.449
PSA ratio (before the operation/12 months after the operation)	2.4 ± 2.9	1.6 ± 1.0	0.180

ThuVEP, vapoenucleation of the prostate using a high-power thulium laser; TURP, transurethral resection of the prostate; PSA, prostate-specific antigen.
The duration of catheterization and postoperative hospitalization showed statistical differences. The estimated residual prostate volume (V2) was calculated as the volume of the entire gland using prolate elliptical formula (height × width × length × π/6) minus the central defect (also calculated using the prolate elliptical formula). The estimated residual prostate volume ratio was calculated as V2/V1.
(*Statistical difference).

ISSN: 1471-2490